· Published by Health Canada · Official notice
This is duplicated text of a letter from Amgen Canada Inc.
Contact the company for a copy of any references, attachments or enclosures.
May 31, 2012
Subject: Xgeva® (denosumab) - Risk of decrease in blood calcium level with severe symptoms, including death
Amgen Canada Inc., in consultation with Health Canada, would like to inform you of new important safety information related to hypocalcemia (low calcium levels in the blood) associated with the use of Xgeva.
Xgeva is used for reducing the risk of developing cancer-related complications like broken bones and/or bone pain that need surgery or radiation. Xgeva is not used for reducing the risk of developing cancer-related complications in patients with multiple myeloma. Xgeva is administered as a single 120 mg injection under the skin given once every 4 weeks.
Amgen Canada is working with Health Canada to update the safety information for Xgeva and has sent a letter to health care professionals to inform them of this new important safety information. A copy of that letter is available on the Health Canada Web site. This information is also available on the Amgen Canada Web site. Amgen Canada will continue to review new safety data for Xgeva, including post-marketing adverse event reports.
Managing marketed health product-related adverse reactions depends on health care professionals and consumers reporting them. Reporting rates determined on the basis of spontaneously reported post-marketing adverse reactions are generally presumed to underestimate the risks associated with health product treatments. Any case of severe symptomatic hypocalcemia or other serious or unexpected adverse reactions in patients receiving Xgeva (denosumab) should be reported to Amgen Canada Inc. or Health Canada at the following addresses:
Amgen Canada Inc.
6775 Financial Drive, Suite 100
Mississauga, Ontario L5N 0A4
Safety Tel: 1-866-512-6436 or Fax: 1-888-264-3655
Safety e-mail: safetycanada@amgen.com
To report suspected adverse reactions to these or other health products, please contact Health Canada's Canada Vigilance Program toll-free at 1-866-234-2345, or visit the MedEffect™ Canada Web site for information on how to report.
The Reporting Forms, postage paid labels, and Guidelines can be found on the MedEffect™ Canada Web site in the Adverse Reaction Reporting section. The Reporting Form is also in the Canadian Compendium of Pharmaceuticals and Specialties.
For other health product inquiries related to this communication, please contact Health Canada at:
Marketed Health Products Directorate
E-mail: mhpd_dpsc.public@hc-sc.gc.ca
Telephone: 613-954-6522
Fax: 613-952-7738
Sincerely,
original signed by
Clive Ward-Able, MD
Executive Medical Director